Microcap Ledger Marker Therapeutics, Inc. $MRKR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Houston, TX
- Fiscal year end
- December 31
- Shares outstanding
- 16,673,127 [10-Q 2026-08-14]
What the company doesAI summary of filing
Marker Therapeutics is a clinical-stage immuno-oncology company developing MAR-T cell therapies, which are non-genetically modified T cell products designed to recognize and kill cancer cells expressing multiple tumor-associated antigens. The company is advancing two product candidates through clinical trials: MT-601, an autologous MAR-T cell therapy for lymphoma and pancreatic cancer, and MT-401-OTS, an off-the-shelf MAR-T cell therapy for acute myeloid leukemia and myelodysplastic syndrome. The company does not currently generate revenue from product sales and is funded through research grants and equity financing. [10-K 2026-03-18]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$5.01M | −$5.12M | $11.33M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $3.55M | −$12.16M | −$12.01M | $16.07M | [10-K 2026-03-18] |
| FY ended Dec 2024 | $6.59M | −$10.73M | −$10.91M | $19.19M | [10-K 2026-03-18] |
- Quarterly cash burn
- −$2.56M
- Cash runway Estimate
- ~13.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 8,923,490 | [10-Q 2024-11-14] |
| 2025-03-18 | 10,709,005 | [10-K 2025-03-31] |
| 2025-05-08 | 11,314,835 | [10-Q 2025-05-15] |
| 2025-08-04 | 12,938,910 | [10-Q 2025-08-14] |
| 2025-11-06 | 16,673,127 | [10-Q 2025-11-13] |
| 2026-03-16 | 16,673,127 | [10-K 2026-03-18] |
| 2026-05-08 | 16,673,127 | [10-Q 2026-05-15] |
| 2026-08-07 | 16,673,127 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2025-01-10; declared effective 2025-01-17 [S-3 2025-01-10]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-05-04 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-03-20 | DEF 14A | Proxy statement |
| 2026-03-19 | 8-K | Results of operations |
| 2026-03-18 | 10-K | Annual report |
| 2026-03-10 | PRE 14A | Proxy statement |
| 2025-11-17 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2025-11-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2025-11-14 | 8-K | Results of operations |
| 2025-11-13 | 10-Q | Quarterly report |
| 2025-11-05 | 8-K | Director or officer change; Other events |
Alerts for $MRKR
Email me when Marker Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.